Drug Trial Radar · NCT06663748
ARX788 in HER2-positive Metastatic Breast Cancer Patients
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Jun 16, 2025
Primary completion
Nov 20, 2027
Study completion Nov 20, 2029
Sponsor
- Lead sponsor
- Henan Cancer HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Oct 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2 study of ARX788 given every 6 weeks in HER2-positive, metastatic breast cancer patients.
Conditions
- HER2-positive, Metastatic Breast Cancer
Interventions
ARX788Drug
2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective remission rate (ORR)Time frame: up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.